ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1503

The Suppressive Ability Of Altered Peptide Ligands To M3R Reactive T Cells In M3R Induced Autoimmune Sialadenitis

Hiromitsu Asashima1, Hiroto Tsuboi1, Naomi Matsuo1, Chihiro Hagiya1, Tomoya Hirota1, Mana Iizuka1, Yuya Kondo1, Isao Matsumoto2 and Takayuki Sumida1, 1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antigens, mouse model and treatment, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous studies have shown that Rag1-/- mice transferred with splenocytes of M3 muscarinic acetylcoline receptor (M3R)-/- mice immunized with M3R peptides mixture (three N-terminal regions; N1, N2, N3, and three extracellular loops; 1st, 2nd, 3rd) (M3R-/-→Rag1-/-) developed sialadenitis like Sjögren’s syndrome (M3R induced autoimmune sialadenitis; MIS). Besides, altered peptide ligands (APLs), the peptides with substitutions in amino acid residues at T-cell receptor contact sites, are reported to regulate the activation of T cells. To develop antigen-specific therapy, we tried to clarify the T cell epitopes of M3R reactive T cells in MIS and also to evaluate the antagonistic APLs.

Methods:

1) Splenocytes of M3R-/- mice immunized with M3R peptides mixture were cultured with each M3R peptide. The cytokines (IFN-g, IL-17, and Il-4) production was measured by ELISA. Similarly, the splenocytes of M3R-/- mice immunized with each N1 and 1st peptide, which was the candidate for the T cell epitopes, and the combination of N1 and 1st peptides were cultured and evaluated.

2) The splenocytes of M3R-/- mice, immunized with N1 alone, 1st alone, the combination of N1 and 1st peptides, or PBS as control were transferred into Rag1-/- mice (each M3R-/-→Rag1-/-, M3R-/-<1st>→Rag1-/-, M3R-/-st>→Rag1-/-, and M3R-/-→Rag1-/-). On day 45 after transfer, the salivary glands of Rag1-/- mice were pathologically examined.

3) APLs of each N1 and 1s peptide were designed.

4) CD4+ and CD11c+ cells were isolated from M3R-/- mice immunized with each N1 and 1st peptide. Each APL was loaded to CD11c+ cells pre-cultured with each suboptimal concentration (N1: 1.5 µM, 1st: 4.5 µM) of N1 and 1st peptide. Afterward, CD4+ T cells were added and cytokines (IFN-g and IL-17) production was measured by ELISA.

Results:

1) Splenocytes immunized with M3R peptide mixture produced IL-17 and IFN-g against N1 and 1st peptide. IL-4 production could not be detected. Splenocytes immunized with N1 and 1st peptide produced IL-17 and IFN-g, but  not IL-4, against each corresponding peptide.

2) M3R-/-→Rag1-/-, M3R-/-<1st>→Rag1-/-, and M3R-/-st>→Rag1-/- developed sialoadenitis. The majority of infiltrating cells in salivary glands were CD4+ T cells, only few with CD8+ T cells and B220+ B cells. The focus scores of these mice (1.0±0.3 in M3R-/-st>→Rag1-/-, 1.3±0.3 in M3R-/-→Rag1-/-, and 0.7±0.3 in M3R-/-<1st>→Rag1-/-) were significantly higher than that of control mice (0.1±0.2 in M3R-/-→Rag1-/-) (p<0.05).

3) Seven APLs of N1 peptide (N1-APL 1-7) and eight APLs of 1st peptide (1st-APL 1-8) were designed.

4) N1-APL5 (AA15 N→T), N1-APL6 (AA15 N→C) and N1-APL7 (AA15 N→S) suppressed the production of IFN-g (N1-APL5 38.8±11.6 pg/mL, N1-APL6  54.9±16.5 pg/mL, N1-APL7 38.0±15.7 pg/mL, control 363.6±65.1 pg/mL). 1st-APL8 (AA140 A→M) suppressed both IL-17 and IFN-g production (IL-17: 1st-APL8 403.4±14.1 pg/mL, control 720.3±49.0 pg/mL. IFN-g: 1st-APL8 185.4±1.6 pg/mL, control 268.8±94.8 pg/mL).

Conclusion: The major T cell epitopes in MIS might be both N1 terminal region and 1st extracellular loops of M3R. N1-APL5, 6, 7 and 1st-APL8 were the candidate for antagonistic APLs, which might have a possibility to suppress MIS in vivo.


Disclosure:

H. Asashima,
None;

H. Tsuboi,
None;

N. Matsuo,
None;

C. Hagiya,
None;

T. Hirota,
None;

M. Iizuka,
None;

Y. Kondo,
None;

I. Matsumoto,
None;

T. Sumida,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-suppressive-ability-of-altered-peptide-ligands-to-m3r-reactive-t-cells-in-m3r-induced-autoimmune-sialadenitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology